viewCaleres Inc

Shares of Famous Footwear owner Caleres dips on 1Q earning miss

Famous Footwear also saw same-store sales decline 1% year-over-year

Wall of shoes
The shoe seller brought in earnings of $0.22 per share, nearly half what it earned in the year-ago quarter

Caleres Inc (NYSE:CAL), which owns Famous Footwear among other brands, posted first-quarter earnings that fell short of expectations as the shoe chain struggled to start 2019.

The company brought in earnings of $0.22 per share, nearly half what it earned in the year-ago quarter. Analysts had called for earnings of $0.36 perare.

Consolidated sales grew 7.2% to $677.8 million, just ahead of Wall Street expectations of $673.2 million. Net income shrunk to $9.1 million from $17.2 million.

The stock lost its footing after hours, falling 2% to $19.

Famous Footware same-store sales declined 1% year-over-year, and its net sales dropped 3% to $352.2 million.

“At Famous Footwear, while the quarter ended on an encouraging note – with positive same-store-sales for both March and April – the slow start in February was tough to overcome,” CEO Diane Sullivan said. “Going forward, we expect to see softness at Famous Footwear through at least the second quarter, as we continue to prepare for back-to-school by aggressively clearing underperforming inventory.”

The St. Louis-based company adjusted its guidance accordingly, lowering its projected full-year earnings to between $2.35 to $2.45 a share from between $2.45 and $2.55 a share. Analysts expect an average earnings of $2.48 per share.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Caleres Inc

Price: 14.27 USD

Market: NYSE
Market Cap: $578.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Genprex sees newly licensed diabetes gene therapy as an...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed diabetes gene...

2 days, 1 hour ago

2 min read